We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$19.2M
Cap. Flow
+$80.6M
Cap. Flow %
16.65%
Top 10 Hldgs %
73.12%
Holding
59
New
4
Increased
1
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$76.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$6.17M
3
ATYR
aTyr Pharma
ATYR
+$3.83M
4
INZY
Inozyme Pharma
INZY
+$1.33M
5
CYPH
Cypherpunk Technologies Inc
CYPH
+$444K

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.65M
2
ALBO
Albireo Pharma Inc
ALBO
+$2.16M
3
ACLX
Arcellx
ACLX
+$1.45M
4
SWTX
SpringWorks Therapeutics
SWTX
+$578K
5
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$195K

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$119M 24.7%
5,161,888
– –
MLYS icon
2
Mineralys Therapeutics
MLYS
$2.46B
$70.8M 14.63%
+4,519,361
New +$76.1M
SRRK icon
3
Scholar Rock
SRRK
$5.95B
$36.8M 7.6%
4,598,828
– –
ACLX
4
DELISTED
Arcellx
ACLX
$28M 5.79%
909,579
-47,872
-5% -$1.45M
LENZ
5
LENZ Therapeutics
LENZ
$184M
$20.7M 4.28%
1,208,473
– –
RAIN
6
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$19.8M 4.08%
2,260,652
– –
ISEE
7
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.7M 3.45%
686,835
-121,206
-15% -$2.65M
ZYME icon
8
Zymeworks
ZYME
$1.71B
$14.7M 3.03%
1,620,687
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$14M 2.88%
695,001
– –
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$12.9M 2.67%
1,409,409
+750,000
+114% +$6.17M
NKTX icon
11
Nkarta
NKTX
$170M
$10.2M 2.1%
2,868,035
– –
HLVX
12
DELISTED
HilleVax
HLVX
$10.1M 2.08%
609,862
-200
-0% -$3.2K
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$8.6M 1.78%
640,688
– –
PEPG icon
14
PepGen
PEPG
$133M
$7.96M 1.65%
651,050
– –
STRO icon
15
Sutro Biopharma
STRO
$394M
$7.74M 1.6%
167,558
– –
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
$6.52M 1.35%
1,693,736
– –
RYTM icon
17
Rhythm Pharmaceuticals
RYTM
$7.38B
$6.16M 1.27%
345,293
– –
DICE
18
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$5.81M 1.2%
202,773
– –
PRME icon
19
Prime Medicine
PRME
$560M
$5.78M 1.2%
470,304
– –
ACRS icon
20
Aclaris Therapeutics
ACRS
$758M
$5.63M 1.16%
696,171
– –
AMYT
21
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$4.44M 0.92%
304,715
– –
JANX icon
22
Janux Therapeutics
JANX
$957M
$4.36M 0.9%
360,414
– –
IMCR icon
23
Immunocore
IMCR
$1.77B
$4M 0.83%
80,963
– –
ATYR
24
aTyr Pharma
ATYR
$47.8M
$3.67M 0.76%
+1,750,000
New +$3.83M
LYRA
25
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.57M 0.74%
35,545
– –
1
2 3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q1 2023 Portfolio in Review

As of Q1 2023, Samsara BioCapital held 59 positions worth $484M, up 4.1% from $465M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Samsara BioCapital deployed $80.6M of net new capital in Q1 2023, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Mineralys Therapeutics: 4,519,361 shares worth $70.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $2.65M trimmed.

  • Samsara BioCapital's largest Q1 2023 buy was Mineralys Therapeutics: 4,519,361 shares worth $70.8M.
  • Samsara BioCapital added most to Avadel Pharmaceuticals in Q1 2023, an estimated $6.17M increase.
  • Samsara BioCapital's biggest Q1 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $2.65M.
  • Samsara BioCapital fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $2.16M.
  • Samsara BioCapital's ten largest holdings make up 73% of its $484M portfolio in Q1 2023.
  • Samsara BioCapital opened 4 new positions and closed 3 in Q1 2023.
  • Samsara BioCapital's portfolio value rose 4.1% quarter-over-quarter to $484M.

Based on Samsara BioCapital's 13F filing for Q1 2023, filed 15 May 2023.